Literature DB >> 24458098

Primary orthotopic glioma xenografts recapitulate infiltrative growth and isocitrate dehydrogenase I mutation.

J Geraldo Valadez1, Anuraag Sarangi, Christopher J Lundberg, Michael K Cooper.   

Abstract

Malignant gliomas constitute a heterogeneous group of highly infiltrative glial neoplasms with distinct clinical and molecular features. Primary orthotopic xenografts recapitulate the histopathological and molecular features of malignant glioma subtypes in preclinical animal models. To model WHO grades III and IV malignant gliomas in transplantation assays, human tumor cells are xenografted into an orthotopic site, the brain, of immunocompromised mice. In contrast to secondary xenografts that utilize cultured tumor cells, human glioma cells are dissociated from resected specimens and transplanted without prior passage in tissue culture to generate primary xenografts. The procedure in this report details tumor sample preparation, intracranial transplantation into immunocompromised mice, monitoring for tumor engraftment and tumor harvesting for subsequent passage into recipient animals or analysis. Tumor cell preparation requires 2 hr and surgical procedure requires 20 min/animal.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24458098      PMCID: PMC4396882          DOI: 10.3791/50865

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  22 in total

Review 1.  50 years of preclinical anticancer drug screening: empirical to target-driven approaches.

Authors:  Marie Suggitt; Michael C Bibby
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

Review 2.  Genetic modeling of gliomas in mice: new tools to tackle old problems.

Authors:  Dolores Hambardzumyan; Luis F Parada; Eric C Holland; Al Charest
Journal:  Glia       Date:  2011-02-08       Impact factor: 7.452

3.  Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.

Authors:  Leonard D Shultz; Bonnie L Lyons; Lisa M Burzenski; Bruce Gott; Xiaohua Chen; Stanley Chaleff; Malak Kotb; Stephen D Gillies; Marie King; Julie Mangada; Dale L Greiner; Rupert Handgretinger
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

4.  Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation.

Authors:  J Gerardo Valadez; Vandana K Grover; Melissa D Carter; M Wade Calcutt; Sunday A Abiria; Christopher J Lundberg; Thomas V Williams; Michael K Cooper
Journal:  Cancer Lett       Date:  2012-10-11       Impact factor: 8.679

Review 5.  Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved.

Authors:  Robert S Kerbel
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

6.  Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma.

Authors:  Qin Shu; Kwong Kwok Wong; Jack M Su; Adekunle M Adesina; Li Tian Yu; Yvonne T M Tsang; Barbara C Antalffy; Patricia Baxter; Laszlo Perlaky; Jianhua Yang; Robert C Dauser; Murali Chintagumpala; Susan M Blaney; Ching C Lau; Xiao-Nan Li
Journal:  Stem Cells       Date:  2008-04-10       Impact factor: 6.277

7.  Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR.

Authors:  Ajay Pandita; Kenneth D Aldape; Gelareh Zadeh; Abhijit Guha; C David James
Journal:  Genes Chromosomes Cancer       Date:  2004-01       Impact factor: 5.006

8.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

9.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Authors:  J I Johnson; S Decker; D Zaharevitz; L V Rubinstein; J M Venditti; S Schepartz; S Kalyandrug; M Christian; S Arbuck; M Hollingshead; E A Sausville
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

10.  Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions.

Authors:  S Piaskowski; M Bienkowski; E Stoczynska-Fidelus; R Stawski; M Sieruta; M Szybka; W Papierz; M Wolanczyk; D J Jaskolski; P P Liberski; P Rieske
Journal:  Br J Cancer       Date:  2011-02-15       Impact factor: 7.640

View more
  6 in total

1.  LncRNA PVT1 Facilitates Tumorigenesis and Progression of Glioma via Regulation of MiR-128-3p/GREM1 Axis and BMP Signaling Pathway.

Authors:  Chao Fu; Dongyuan Li; Xiaonan Zhang; Naijie Liu; Guonan Chi; Xingyi Jin
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

2.  Creating anatomically accurate and reproducible intracranial xenografts of human brain tumors.

Authors:  Angela M Pierce; Amy K Keating
Journal:  J Vis Exp       Date:  2014-09-24       Impact factor: 1.355

3.  Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.

Authors:  Junfeng Zhang; Wei Xue; Kai Xu; Liang Yi; Yu Guo; Tian Xie; Haipeng Tong; Bo Zhou; Shunan Wang; Qing Li; Heng Liu; Xiao Chen; Jingqin Fang; Weiguo Zhang
Journal:  Theranostics       Date:  2020-06-05       Impact factor: 11.556

4.  LncRNA PCGEM1 contributes to malignant behaviors of glioma by regulating miR-539-5p/CDK6 axis.

Authors:  Shu-Li Liu; Mao-Hua Chen; Xiao-Bo Wang; Rong-Kai You; Xue-Wei An; Qiu Zhao; Ren-Shu Wang
Journal:  Aging (Albany NY)       Date:  2021-02-11       Impact factor: 5.682

5.  Successful Treatment of Intracranial Glioblastoma Xenografts With a Monoamine Oxidase B-Activated Pro-Drug.

Authors:  Martyn A Sharpe; Andrew D Livingston; Taylor L Gist; Pardip Ghosh; Junyan Han; David S Baskin
Journal:  EBioMedicine       Date:  2015-08-08       Impact factor: 8.143

6.  A new glioma grading model based on histopathology and Bone Morphogenetic Protein 2 mRNA expression.

Authors:  Kaijia Zhou; Zheng Zhao; Shouwei Li; Yanwei Liu; Guanzhang Li; Tao Jiang
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.